Can chemotherapy reboot immunotherapy in resistant melanoma?
NCT ID NCT04225390
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tested whether giving the chemotherapy drug dacarbazine (DTIC) before re-trying immunotherapy could help patients with advanced melanoma whose cancer had stopped responding to immunotherapy. The study enrolled 38 adults with metastatic melanoma that had progressed after PD-1/PD-L1 or PD-1 plus CTLA-4 blockade. The goal was to see if DTIC could break resistance and allow immunotherapy to work again.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
dacarbazine (DTIC)
What this could lead to
If successful, this approach could offer a new way to overcome resistance to immunotherapy in advanced melanoma patients.
What could go wrong
This is a small, single-arm phase 2 trial with only 38 participants, so results may not apply broadly. The treatment may not improve outcomes and could cause side effects from chemotherapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IMMUNOTHERAPY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University Hospital
Erlangen, Bavaria, 91054, Germany